Literature DB >> 27185700

Major complications of regional anesthesia in 11 teaching hospitals of China: a prospective survey of 106,569 cases.

Tingting Huo1, Li Sun1, Su Min2, Wenzhi Li3, Xinhua Heng4, Lijun Tang5, Shengmei Zhu6, Hailong Dong1, Qiang Wang1, Lize Xiong7.   

Abstract

STUDY
OBJECTIVE: To determine the incidence of major complications in patients undergoing regional anesthesia (RA) in China.
DESIGN: Multicenter prospective survey.
SETTING: Eleven teaching hospitals in China. PATIENTS AND
INTERVENTIONS: A total of 106,569 patients undergoing RA from April 1, 2009, to April 30, 2011, were involved. MEASUREMENT: Information on patients, types of surgery, and RA techniques was collected with a standardized chart. After RA, the patients were followed up by an investigator in each center for 1 to 3 weeks according to the patient's condition. Data were integrated and analyzed with a structured query language server system. MAIN
RESULTS: Among the patients undergoing RA, 37 developed major complications, including Horner syndrome (n = 9; 0.84/10,000), recurrent laryngeal nerve blockade (n = 6; 0.56/10,000), cardiac arrest (n = 1; 0.09/10,000), hematoma (n = 2; 0.19/10,000), seizures (n = 5; 0.46/10,000), catheter break (n = 1; 0.09/10,000), paraplegia (n = 1; 0.09/10,000), cauda equina syndrome (n = 2; 0.19/10,000), and extensive neuraxial block (n = 10; 0.94/10,000). The incidence of major RA complications varied from 0.8/10,000 to 18.8/10,000 among centers and was highest in cervical plexum block. Plastic surgery had the highest incidence of complications (19.0/10,000), most of which were recurrent extensive neuraxial block. The total incidence of major RA complications was 3.47/10,000.
CONCLUSION: This large, multicenter, prospective survey revealed the incidence of major complications after RA in China's hospitals. Although severe complication like cardiac arrest is rare, it is distressing and challenging. Hence, there is still a room to improve on daily basis to further reduce complications related to RA.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiac arrest; Complications; Horner syndrome; Incidence; Neuraxial block; Regional anesthesia

Mesh:

Year:  2016        PMID: 27185700     DOI: 10.1016/j.jclinane.2016.01.022

Source DB:  PubMed          Journal:  J Clin Anesth        ISSN: 0952-8180            Impact factor:   9.452


  6 in total

1.  Surgeon administered direct adductor canal block is as good as ultrasound guided adductor canal block in pain management in knee replacements- A retrospective case-control study.

Authors:  Prashant Pawar; Manan Shah; Nilen Shah; Anjali Tiwari; Dipit Sahu; Vaibhav Bagaria
Journal:  J Orthop       Date:  2022-04-22

2.  Retrospective study of perioperative cardiac arrest from a Chinese tertiary hospital.

Authors:  Huili Kan; Yonghong Ding; Shanshan Wu; Zongwang Zhang
Journal:  Medicine (Baltimore)       Date:  2021-08-13       Impact factor: 1.817

3.  Neurotoxicity Comparison of Two Types of Local Anaesthetics: Amide-Bupivacaine versus Ester-Procaine.

Authors:  Xu-Jiao Yu; Wei Zhao; Yu-Jie Li; Feng-Xian Li; Zhong-Jie Liu; Hua-Li Xu; Lu-Ying Lai; Rui Xu; Shi-Yuan Xu
Journal:  Sci Rep       Date:  2017-03-24       Impact factor: 4.379

4.  A retrospective study of mortality for perioperative cardiac arrests toward a personalized treatment.

Authors:  Huijie Shang; Qinjun Chu; Muhuo Ji; Jin Guo; Haotian Ye; Shasha Zheng; Jianjun Yang
Journal:  Sci Rep       Date:  2022-08-12       Impact factor: 4.996

5.  A study of anaesthesia-related cardiac arrest from a Chinese tertiary hospital.

Authors:  Chu-Lian Gong; Jing-Ping Hu; Zhuo-Lin Qiu; Qian-Qian Zhu; Zi-Qing Hei; Shao-Li Zhou; Xiang Li
Journal:  BMC Anesthesiol       Date:  2018-09-11       Impact factor: 2.217

6.  Case Report of a Massive Thigh Hematoma after Adductor Canal Block in a Morbidly Obese Woman Anticoagulated with Apixaban.

Authors:  Katherine L Koniuch; Bradley Harris; Michael J Buys; Adam W Meier
Journal:  Case Rep Anesthesiol       Date:  2018-08-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.